At the same time, purified mAbs began to be used in the development of antibody‐based detection systems for SARS‐CoV‐2 diagnosis.For each assignment, you will complete the following steps: Thanks to its high response to RBD, a neutralizing antibody candidate was obtained for potential drug development. As a conclusion 2 mAbs were obtained, one of them was only specific to S1 protein, but the other one could detect RBD protein at the same level as S1 protein even was immunized with S1 protein. Therewithal, the isotype of the developed antibodies was determined as IgG1 and the productivity of purification processes was compared by using Protein A and Protein G columns. Selection and subcloning processes were performed for the hybridoma cells which have high‐level antibody response, after that, the specificity of the developed mAbs to SARS‐CoV‐2 proteins was demonstrated by enzyme‐linked immunosorbent assay (ELISA) and western blotting methods. Spleen cells of the immunized mice which have high antibody response were fused with mouse myeloma cells (F0 ATTC CRL‐1646) in the presence of polyethylene glycol to obtain hybrid cells.

BALB/c mice were immunized with the recombinant S1 and RBD proteins. In this study, mouse mAbs against the receptor‐binding domain (RBD) and S1 subunit of the spike protein which are structural proteins of SARS‐CoV‐2, were developed using hybridoma technology. There is a need for the use of high‐affinity antibodies specific to SARS‐CoV‐2 in the rapid and accurate diagnosis of the global COVID‐19 outbreak. Monoclonal antibodies (mAbs) are used clinically in the diagnosis and therapy of many diseases.

Wolfram mathematica free trial